Treatment of Dientamoeba Fragilis Infection With Paromomycin

Vandenberg, Olivier; Souayah, Hichem; Mouchet, Françoise; Dediste, Anne; Gool, Tom van

doi:10.1097/01.inf.0000247139.89191.91

Cited by 33 publications

(28 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, this study is not directly comparable to the current study. To our knowledge, no other studies report on the effect of eradication of D. fragilis in IBS patients, but clinical improvement of gastrointestinal symptoms other than IBS linked to eradication of D. fragilis have been described 24,31,44,45,47,[53][54][55][56][57][58][59][60] suggesting that at least in some individuals D. fragilis is pathogenic. Only two epidemiologic studies deal with the association between D. fragilis and IBS.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Dientamoeba fragilis in Patients with Irritable Bowel Syndrome

Engsbro

Stensvold²,

Nielsen³

et al. 2012

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. The role of Dientamoeba fragilis in irritable bowel syndrome (IBS) is incompletely known. We aimed to investigate whether eradication of D. fragilis alleviates symptoms in IBS. Twenty-five D. fragilis-positive IBS patients were treated with Metronidazole (MZ) or Tetracycline. The patients were mostly female (89%), and mean age (SD) was 35.1 (8.2) years. Microbiological response, evaluated 2 weeks post-treatment, was observed in 15 of 25 patients (60%), all by MZ. Clinical response, defined as adequate relief of symptoms, was observed in 7 of 22 patients (32%), all by MZ. In a logistic regression analysis, we found no significant association between clinical and microbiological response. This case study did not support our hypothesis of a simple association between D. fragilis and IBS. Some D. fragilis-infections were insufficiently treated by MZ. Further studies into the prevalence and effect of eradication of D. fragilis in IBS and into efficient treatments of D. fragilis are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Dientamoeba fragilis in Patients with Irritable Bowel Syndrome

Engsbro

Stensvold²,

Nielsen³

et al. 2012

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…Various antimicrobial therapies have resulted in the successful clearance of D. fragilis and total resolution of gastrointestinal symptoms in infected patients (152,387,445). Paromomycin, secnidazole, iodoquinol, tetracycline, ornidazole, and metronidazole have been used successfully to treat D. fragilis infections (22,152,305,445).…”

Section: Dientamoeba Fragilismentioning

confidence: 99%

Enteric Protozoa in the Developed World: a Public Health Perspective

et al. 2012

View full text Add to dashboard Cite

SUMMARY Several enteric protozoa cause severe morbidity and mortality in both humans and animals worldwide. In developed settings, enteric protozoa are often ignored as a cause of diarrheal illness due to better hygiene conditions, and as such, very little effort is used toward laboratory diagnosis. Although these protozoa contribute to the high burden of infectious diseases, estimates of their true prevalence are sometimes affected by the lack of sensitive diagnostic techniques to detect them in clinical and environmental specimens. Despite recent advances in the epidemiology, molecular biology, and treatment of protozoan illnesses, gaps in knowledge still exist, requiring further research. There is evidence that climate-related changes will contribute to their burden due to displacement of ecosystems and human and animal populations, increases in atmospheric temperature, flooding and other environmental conditions suitable for transmission, and the need for the reuse of alternative water sources to meet growing population needs. This review discusses the common enteric protozoa from a public health perspective, highlighting their epidemiology, modes of transmission, prevention, and control. It also discusses the potential impact of climate changes on their epidemiology and the issues surrounding waterborne transmission and suggests a multidisciplinary approach to their prevention and control.

show abstract

“…4,11,12 Numerous studies have shown antimicrobial therapy targeting and eliminating D. fragilis will result in marked clinical improvement for patients suffering from dientamoebiasis. 3,12,13 All patients from both families presented with a repeated D. fragilis infection over prolonged periods of time. Bacterial etiological agents were excluded by routine testing.…”

Section: Discussionmentioning

confidence: 99%